Ronald Petersen, MD, PhD, discusses the implications of Eli Lilly's failed solanezumab trial on the future of Alzheimer's disease research.
Men with autoimmune diseases demonstrated a greater risk for dementia than women, especially women with multiple sclerosis.
Mindfulness meditation was associated with improvements in measures of anxiety, depression, and negative thoughts.
Patients with the K-variant of the butyrylcholinesterase gene have an adverse reaction to treatment with donepezil.
As dementia worsens, caregivers often have to report symptoms on behalf of the patient, and they tend to report more depressive symptoms than patients do.
Mixed AD neuropathologic changes were more frequent than pure ADNC pathology among the group that remained MCI until death.
Researchers found that people who slept 9 or more hours per night were at an increased risk of dementia.
Early intervention in patients with heart failure or atrial fibrillation may help delay or prevent the onset of mild dementia.
In a review, researchers found that elevated levels of albuminuria were linked to worse global cognitive performance and accelerated cognitive decline.
The combination treatment may have benefits, especially for patients who are unresponsive to donezepil alone.
The investigators believe the association is related to exposure to pollutants from cars and roads.
Memantine therapy may put users at greater risk of developing pneumonia.
Increasing severity of AD pathology inversely correlated to decreases in time from motor symptoms to dementia onset and death.
Hormone therapy may reduce risk for death from vascular dementia in older women.
Patients experienced a 34% risk of a reduction in the ability to perform daily tasks independently.
Amyloid beta protein accumulation was present in the hearts of patients with Alzheimer's disease.
There is a clear lack of evidence in the pharmacologic guidance of sleep problems in dementia.
Patients with Alzheimer's disease tended to have increased thickness in the wall of their left ventricle.
The present findings, in combination with those from prior observational research, provide a solid rationale for further randomized trials.
There seems to be no effect on everyday functioning.
Eli Lilly's investigational Alzheimer's drug failed to meet the primary end point in the phase 3 EXPEDITION3 trial.
Neurology Advisor Articles
- New Sleep Apnea Clinical Practice Guidelines
- International League Against Epilepsy Updates Epilepsy Classification System
- In Refractory Status Epilepticus, Lacosamide May Be a Good Option
- Patent Foramen Ovale Closure Reduces Stroke Risk in Patients With Inherited Thrombophilias
- The Handoff: Your Week in Neurology News - 3/23/17
- Q&A: Strategies for Transitioning Pediatric Patients to Adult Care
- Epilepsy Risk May Increase After Incident Depression
- Alzheimer's Caregiver Coping Program Does Not Increase Health Care Costs
- Valproate for Epilepsy Poses Greater Risk for Major Congenital Malformations
- VTE Recurrence Decreased With Rivaroxaban